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Abstract
Background: At many centres tumour markers are used to detect disease recurrence and to
monitor response to therapy in patients with advanced disease, although the real value of serial
observation of marker levels remains disputed. In this study, we evaluated the prognostic value of
tumour markers for predicting response (partial response [PR], stable disease [SD] ≥ 6 months),
de novo disease progression (PD) and secondary PD in patients receiving fulvestrant ('Faslodex') 250
mg/month for the treatment of metastatic breast cancer (MBC).
Methods: Changes in cancer antigen 15–3 (CA 15-3) and carcinoembryonic antigen (CEA) were
prospectively monitored (monthly) and were also evaluated for the 3 months preceding secondary
PD. Data from 67 patients with previously treated MBC participating in a Compassionate Use
Programme were analysed.
Results: In patients with a PR (n = 7 [10.4%]), a non-significant increase in CA 15-3 occurred during
the first 6 months of treatment; CEA was significantly reduced (P = 0.0165). In patients with SD ≥
6 months (n = 28 [41.8%]), both CA 15-3 (P < 0.0001) and CEA (P = 0.0399) levels increased
significantly after 6 months treatment. In those experiencing de novo PD (n = 32 [47.8%]), CA 15-
3 increased significantly (P < 0.0001) after 4 months; CEA also increased significantly (P = 0.0002)
during the same time period. Both CA 15-3 (P  < 0.0001) and CEA (P  < 0.0001) increased
significantly in the 3 months preceding secondary PD.
Conclusion: CA 15-3 increases in patients progressing on fulvestrant but may also increase in
those experiencing clinical benefit; this should not be taken as a sign of PD without verification.
Overall, both CA 15-3 and CEA appear to be poor prognostic markers for determining progression
in patients receiving fulvestrant.
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Background
Tumour markers are often used to detect disease recur-
rence after primary treatment for cancer [1,2] and to mon-
itor response to therapy in patients with advanced disease
[3]. In breast cancer, the most widely adopted combina-
tion of tumour markers are carcinoembryonic antigen
(CEA) and mucin (MUC1), commonly detected as cancer
antigen (CA) 15-3 [4]. Of these two markers, CA 15-3 is
generally regarded as the most specific and sensitive. From
as early as 1978 investigators were examining the prog-
nostic value of CEA in patients receiving endocrine ther-
apy for the treatment of metastatic breast cancer (MBC)
[5], but the value of tumour markers in monitoring
response to fulvestrant ('Faslodex') treatment has not pre-
viously been evaluated.
It is commonly believed that an increase in tumour
marker levels may be a sign of de novo disease progression
(PD), thus signalling that a change in therapy may be nec-
essary [6]. A recent prospective study found that the
changes in serum tumour marker levels after the start of
therapy correlate significantly with therapy response; and
a greater than 20% reduction in marker levels was a
favourable predictive factor for time to progression during
systemic treatment [7]. However, in 1996 Sonoo sug-
gested that serial levels of tumour markers taken during
therapy might not always correlate with therapy response
[8]. This group observed an initial increase and subse-
quent decrease in tumour marker levels in up to one-third
of patients experiencing clinical benefit (CB). One reason
for this spike phenomenon might be the possible tumour
flair associated with the partial agonistic properties of
selective estrogen receptor modulators (SERMs), which
however was not observed with fulvestrant yet. A possible
alternative explanation for this spike is that it results from
the destruction of tumour cells on successful treatment,
similar to the increase in muscle enzymes observed fol-
lowing myocardial infarction. Another group recently
observed that changes in serial tumour marker levels do
not allow prediction of bone scan results [9]. Thus the real
value of serial observation of marker levels remains some-
what disputed.
Fulvestrant is the first of a new type of oestrogen receptor
(ER) antagonist to be licensed for the treatment of
advanced breast cancer [10,11]. Fulvestrant binds, blocks
and degrades the ER, thus decreasing cellular levels of the
ER and minimising the transcription of oestrogen- and
progesterone-dependent genes [12,13]. Two large Pha-
seIII trials have shown that fulvestrant is at least as effec-
tive as anastrozole in the treatment of patients with
advanced breast cancer progressing on/after antioestrogen
therapy [14-17]. It has also been shown to have similar
efficacy as tamoxifen in the first-line treatment of patients
with ER-positive and/or progesterone receptor (PgR)-pos-
itive disease [18]. Here we evaluated the prognostic value
of tumour markers at predicting response and secondary
progression during fulvestrant therapy.
Methods
All data were collected at the Department of Internal Med-
icine I, Division of Oncology at the Medical University of
Vienna, Vienna, Austria. The study was performed in
accordance with the ethical regulations of the Medical
University of Vienna.
Criteria for inclusion were as follows: Presence of at least
one measurable lesion, Karnofsky performance score ≥
70%, life expectancy of >3 months, adequate organ func-
tion as defined by WBC count ≥ 3500/µl, platelet count ≥
100 000/µl, hematocrit ≥ 30% and serum bilirubin and
creatinine ≤ 1.25 × upper limit of the institution's normal
range, and informed consent. We included patients with
marker levels below the cut-offs at the initiation of treat-
ment or dropping below the cut-offs during the course of
fulvestrant treatment. However, patients were excluded
from this study if they never experienced an elevation of
marker levels above cut-offs on treatment.
Table 1: Patient characteristics
Characteristics Patients
Entered 67
Age (years)
Median (range) 62 years (range 39 – 83 y)
Estrogens receptor positive 62 (92.5%)
Progesterone receptor positive 42 (62.7%)
Her2 positive 10 (14.9%)
Adjuvant chemotherapy 27 (40.3%)
Adjuvant endocrine therapy 36 (53.7%)
Palliative chemotherapy 44 (65.7%)
Fulvestrant treatment
1st line 3 (4.5%)
2nd line 27 (40.3%)
3rd line 28 (41.8%)
4th line 9 (13.4%)
Prior endocrine treatment
Tamoxifen 17 (25.4%)
Anastrozole/Letrozole 59 (88.1%)
Exemestane 32 (47.8%)
MPA 1 (1.5%)
Goserelin 1 (1.5%)
Metastatic sites
Lung 19
Liver 20
Bones 44
Lymph nodes 15
Soft tissue 19
Skin 10
Other 1
More than one metastatic site 40 (59.7%)
Number of met. Sites
Median (range) 2 (range 1 – 4)BMC Cancer 2006, 6:81 http://www.biomedcentral.com/1471-2407/6/81
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Fulvestrant was administered monthly as a single 250 mg
intramuscular injection [19] as part of a compassionate
use programme (supported by AstraZeneca) until PD or
other event necessitating withdrawal. All patients were
postmenopausal women with ER-positive and/or PgR-
positive MBC for whom at least one prior endocrine ther-
apy had failed, either as adjuvant treatment or as the treat-
ment of advanced disease. Many had also received
chemotherapy in the adjuvant and/or advanced disease
settings. Table 1 lists the characteristics of all patients
included.
Assessments
Tumour response was assessed every 3 months using
UICC criteria. Partial response (PR) was defined as a ≥
25% reduction in the sum of products of the diameters of
all measurable lesions, no increase in lesion size and no
new lesions. Stable disease (SD) was defined as a <25%
decrease or < 25% increase in the sum of products of the
diameters of all measurable lesions without the appear-
ance of new lesions (maintained for a minimum of 6
months). PD was defined as a >25% increase in lesion size
or the appearance of new lesions. Tumour response was
assessed via computed tomography (CT) scans of the tho-
rax and the abdomen and, where appropriate, also using
magnetic resonance imaging or bone scans. An individual
patient's response was listed as the best overall response
during the course of treatment.
Levels of the tumour markers CA 15-3 and CEA were pro-
spectively monitored on a monthly basis during fulves-
trant treatment (at the time of each injection). Patients
experiencing SD with fulvestrant were retrospectively split
into two groups for the purpose of the analysis of CA 15-
3 levels: those experiencing SD ≥ 6 but < 9 months and
those experiencing SD ≥ 9 months.
We also prospectively investigated whether a rise in CA
15-3 or CEA levels during the course of therapy could pre-
dict secondary progression in patients who had previously
experienced CB (PR or SD ≥ 6 months) with fulvestrant.
For this, tumour marker levels were analysed over the last
3 months of treatment prior to the final response assess-
ment at which the patient was deemed to be progressing.
CEA and CA 15-3 levels were assessed using the specific
CEA and CA 15-3 Elecsys® 2010 reagents (Roche Diagnos-
tics AG, Basel, Switzerland) for Elecsys® 2010 Disc System
(Roche Diagnostics, Basel, Switzerland). Cut-off values of
the assay methods were 3.4 µg/l in CEA and 30 kU/l in CA
15-3.
Statistical analysis
Tumour marker levels (CEA and CA 15-3) were analysed
during the first 6 months of therapy with fulvestrant in all
patients, and 9 months in patients with CB ≥ 9 months.
They were also analysed during the last 3 months of treat-
ment in patients experiencing secondary progression fol-
lowing CB. The Friedman test and GraphPad PRISM
Version 4.00 were used to analyse any observed changes
and to assess their statistical significance.
As no survival analysis was performed, CB was used as sur-
rogate parameter for the evaluation of the prognostic
implication of marker levels.
Results
Patients and response
Tumour marker levels and response were analysed in 67
patients receiving fulvestrant treatment between 2002 and
2004. The median age of the patients was 63 years (range
31–83 years). Seven patients (10.5%) experienced a PR
with fulvestrant treatment, 28 patients (41.8%) experi-
enced SD ≥ 6 months, while 32 patients (47.8%) had de
novo PD.
Tumour marker levels in patients experiencing a PR
In the seven patients experiencing a PR an increase in CA
15-3 levels was observed over the first 4 months of treat-
ment (Table 2); this did not reach statistical significance.
Similar observations were noted after 6 months of treat-
ment. CEA levels showed a non-significant decrease after
3 months of therapy (P = 0.2103), which reached signifi-
cance after 6 months (P = 0.0165).
Tumour marker levels in patients experiencing SD ≥ 6 
months
In the 28 patients with SD ≥ 6 months CA 15–3 serial lev-
els increased significantly between baseline and 4 months
(P = 0.0023) (Table 2; Fig. 1) and were also significantly
increased at 6 months (P < 0.0001). Further assessments
carried out because of this unexpected increase in CA 15-
3 levels were retrospectively evaluated in two separate
subgroups (SD ≥ 6 but < 9 months [n = 14] and SD ≥ 9
months [n = 14]). Between baseline and 4 months a sig-
nificant increase in CA 15-3 levels was observed both in
the SD ≥ 6 but < 9 months (P = 0.0017) and the SD ≥ 9
months (P  = 0.0405) subgroups, both of which were
maintained at 6 months. In the group of patients experi-
encing SD ≥ 6 months overall, CEA levels also increased
significantly between baseline and 6 months (P  =
0.0399).
Tumour marker levels in patients experiencing PD
In the 32 patients experiencing de novo PD a significant
increase (P < 0.0001) in CA 15-3 levels was noted between
baseline and 4 months (Table 2; Fig. 2). CEA levels also
showed a significant increase (P = 0.0002) over the same
period.BMC Cancer 2006, 6:81 http://www.biomedcentral.com/1471-2407/6/81
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Tumour marker levels in those experiencing secondary 
progression
In patients experiencing CB followed by secondary pro-
gression (n = 28), a significant increase in CA 15-3 levels
was observed during the last 3 months of treatment (P <
0.0001) (Fig. 3). CEA levels also increased significantly (P
< 0.0001) during this time.
Discussion
Our group was amongst the first in continental Europe to
treat patients with fulvestrant as part of a compassionate
use programme supported by AstraZeneca. In our institu-
tion it is common practice to evaluate tumour marker lev-
els following each month of palliative therapy. During
informal analysis of such data in patients receiving fulves-
trant, potential differences in tumour marker kinetics
were noted within the subgroup of patients responding to
therapy and thus a detailed investigation was carried out.
In this study a trend towards increased CA 15-3 levels was
noted during the first 3 months in patients responding to
fulvestrant treatment. This trend became stronger over
time, but still failed to reach statistical significance after 6
months of treatment. This result was unexpected since
Table 2: Mean tumour marker levels during fulvestrant treatment
Patient response mean marker levels (+/- SD) (month)
123456789
P-values (1→4 months) P-values (1→6 months)
PR (n = 7)
CA 15-3 144.00 128.54 156.87 178.16 170.19 197.01
(kU/l) +/-171.75 +/-164.90 +/-194.54 +/-227.42 +/-256.43 +/-270.54
N.S. N.S.
CEA 5.31 4.17 3.87 3.81 3.46 4.06
(µg/l) +/-3.96 +/-2.82 +/-2.61 +/-2.54 +/-2.78 +/-2.95
N.S. 0.0165
SD ≥ 6 months (n = 28)
CA 15-3 184.68 214.00 226.54 240.64 269.05 268.61
(kU/l) /-214.08 +/-262.54 +/-297.58 +/-305.39 +/-352.19 +/-338.27
0.0023 < 0.0001
CEA 52.59 43.63 43.49 58.01 55.28 72.70
(µg/l) +/-201.99 +/-153.74 +/-153.73 +/-224.58 +/-203.94 +/-307.61
N.S. 0.0399
SD ≥ 6 < 9 months (n = 14)
CA 15-3 205.21 232.21 265.50 281.07 302.71 309.04
(kU/l) +/-256.19 +/-309.81 +/-378.08 +/-378.57 +/-424.97 +/-429.82
0.0017 0.0002
SD ≥ 9 months (n = 14)
CA 15-3 164.14 195.79 185.57 200.21 214.50 229.07 209.55 258.61 263.29
(kU/l) +/-169.24 +/-215.55 +/-194.18 +/-216.47 +/-229.92 +/-263.48 +/-226.84 +/-283.62 +/-292.21
0.0405 0.0146
De novo PD (n = 32)
CA 15-3 259.91 419.41 441.16 580.31
(kU/l) +/-419.29 +/-994.42 +/-790.95 +/-
1052.69
< 0.0001
CEA 140.61 192.37 199.98 250.09
(µg/l) +/-652.01 +/-902.53 +/-907.67 +/-
1087.32
0.0002
Secondary PD (n = 28)
CA 15-3 411.20a 510.67b 572.50c 698.72d
(kU/l) +/-541.50 +/-834.03 +/-891.17 +/-
1164.36
< 0.0001
CEA 56.32 a 53.46 b 69.99 b 110.32 d
(µg/l) +/-224.80 +/-203.92 +/-269.53 +/-473.03
< 0.0001
PR, partial response; SD, stable disease; PD, disease progression; NS, not statistically significant; a2 months before PD; b1 months before PD; cPD; d1 
month after PDBMC Cancer 2006, 6:81 http://www.biomedcentral.com/1471-2407/6/81
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these patients were responding to fulvestrant therapy. The
only occasion in which CEA appeared to have a higher
predictive value than CA 15-3 was in the subgroup of
patients experiencing a PR, where the observed decrease in
CEA levels attained statistical significance after 6 months.
In the group of patients experiencing SD we found a sig-
nificant increase in CA 15-3 levels at both 3 and 6 months.
This was observed both in patients with SD ≥ 6 months
but < 9 months and in those experiencing SD ≥ 9 months,
thus this observation is unlikely to result from a bias
caused by a lead-time effect to actual PD. There are several
possible explanations for this early increase in tumour
marker levels. First, it may be as a result of the delay in
reaching steady-state levels with fulvestrant treatment
[20], although this appears unlikely as these patients were
already experiencing CB with fulvestrant. Nonetheless it
seems reasonable to ask whether a loading-dose regimen
of fulvestrant may be appropriate and this type of dosing
is under investigation in ongoing clinical trials [21]. How-
ever, as initial increases in CEA and CA 15-3 have also
been observed in patients experiencing CB with other
breast cancer therapies [8,22-25], the dose of fulvestrant
seems unlikely to be the cause. One explanation is that the
increase in tumour markers may result from increased
tumour degradation in response to fulvestrant treatment.
These data may suggest that, in the absence of radiological
detection of PD, fulvestrant treatment should be contin-
ued beyond 3 months before response to therapy is
assessed. Marker levels in patients with de novo PD
increased steadily during fulvestrant treatment as may be
expected in the presence of non-responsive disease. As
tumour marker levels may rise in both responding and
non-responding patients during the first few months of
fulvestrant treatment, it may be that an increase in mark-
ers following a period of stabilisation may be more pre-
dictive of disease progression.
The data presented here suggest that if increased CA 15-3
levels are observed after the first 3 months of fulvestrant
treatment this should not be taken as a sign of PD without
radiological verification. On the contrary, such an
Observed changes in CA 15-3 levels in patients with de novo  disease progression from baseline to 4th treatment (n = 32) Figure 2
Observed changes in CA 15-3 levels in patients with de novo 
disease progression from baseline to 4th treatment (n = 32).
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Observed changes in CA 15-3 levels in patients with stable  disease ≥ 6 months from baseline to 6th treatment (n = 28) Figure 1
Observed changes in CA 15-3 levels in patients with stable 
disease ≥ 6 months from baseline to 6th treatment (n = 28).
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increase may also be observed in patients gaining CB from
treatment. Consequently, our results demonstrate that it is
inappropriate to change therapy purely based on
increased tumour marker levels, as some patients may still
be benefiting from fulvestrant treatment.
In our study CEA levels were found to decrease signifi-
cantly after 6 months in patients experiencing a PR and to
increase significantly in those with SD. Significant rises in
CEA were also observed in patients experiencing de novo
PD.
The predictive value of tumour markers in signalling sec-
ondary progression was also prospectively assessed. We
found that both CA 15-3 and CEA levels increased signif-
icantly during the last 3 months of treatment and so these
markers may be valuable in predicting secondary progres-
sion. However, both the CEA and CA 15-3 data need to be
treated with some caution because of the small number of
patients in this study.
Conclusion
In conclusion, our results suggest that increased CA 15-3
levels may be observed in patients experiencing a PR with
fulvestrant, however, increased CA 15-3 levels are also
possible in patients experiencing either SD or PD. Thus it
is important that such an increase is not taken as a definite
sign of de novo progression without radiological verifica-
tion. An increase in CA 15-3 or CEA levels may also pre-
cede secondary progression in patients who had
previously gained CB from fulvestrant treatment. Overall,
both CA 15-3 and CEA appear to be poor prognostic
markers for determining progression in patients receiving
fulvestrant.
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